BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 15890945)

  • 1. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
    VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
    J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
    Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
    Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.
    Akagi T; Ueno M; Hiraishi K; Baba M; Akashi M
    J Control Release; 2005 Dec; 109(1-3):49-61. PubMed ID: 16256237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella.
    Berggren RE; Wunderlich A; Ziegler E; Schleicher M; Duke RC; Looney D; Fang FC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):489-95. PubMed ID: 8548327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles.
    Yao Q
    Res Initiat Treat Action; 2003; 8(2):20-1. PubMed ID: 12845773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens.
    Okada E; Sasaki S; Ishii N; Aoki I; Yasuda T; Nishioka K; Fukushima J; Miyazaki J; Wahren B; Okuda K
    J Immunol; 1997 Oct; 159(7):3638-47. PubMed ID: 9317164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
    Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.